STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES. STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).
Stocks highlighted in this watchlist include: $INFI, $RNN, $ECYT
INFI: Float of 49.39 million shares with 1.51% short. Working on IPI-549 + Nivolumab Solid Tumors.
An abstract describing new data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), has been selected as a late-breaking presentation during an oral session at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, MD, November 10 - 12. Additionally, a clinical trials in progress poster will also be presented on the Phase 1/1b clinical study which is ongoing to explore the safety and activity of IPI-549 both as a monotherapy and in combination with Opdivo®(nivolumab), a PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors. IPI-549 is believed to be the only PI3K-gamma inhibitor in clinical development.
RNN: Float of 30.73 million shares with 5.35% short.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, Ph.D., the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2017 Healthcare Conference. Dr. Suzdak is scheduled to present at 8:00 a.m. EST on Wednesday, November 15, 2017, in the Henry conference room at the Lotte New York Palace Hotel, New York City.
Yesterday, it announced that it has dosed the first patient in a Phase IIa clinical study of RX-3117 in combination with Abraxane® in patients newly diagnosed with metastatic pancreatic cancer who have had no prior chemotherapy. Abraxane® (albumin-bound paclitaxel) is commonly used in the treatment of pancreatic cancer in combination with other chemotherapies.
ECYT: Float of 38.86 million shares with 7.19% short.
Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Jefferies 2017 London Healthcare Conference on Wednesday, Nov. 15, 2017, at 8:40 a.m. GMT.
ECYT announced it incurred a loss of 27 cents per share in third-quarter 2017 narrower than the Zacks Consensus Estimate of a loss of 35 cents.